Abstract
743P - Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have